開設賬戶
模擬帳戶
關於我們
即時報價及新聞
市場分析
財經日曆
每日市場分析
交易平台
下載及介紹
使用教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
繁
简
EN
客户登入
開設賬戶
模擬帳戶
繁
简
EN
客户登入
開設賬戶
模擬帳戶
關於我們
上志國際介紹
上志國際特點
即時報價及新聞
即時報價
即時新聞
市場分析
財經日曆
市場分析
交易平台
平台特點
平台教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
關於我們
交易細則
貴金屬市場
交易平台
市場分析
推廣和資訊
常見問題
聯絡我們
繁
简
EN
OPEC monthly report raised its 2027 forecast for demand for OPEC crude to 43.9 mln b/d, about 1.6 mln b/d higher than its 2026 forecast.
2026-09-10
OPEC monthly report raised its 2027 forecast for demand for OPEC crude to 43.9 mln b/d, about 1.6 mln b/d higher than its 2026 forecast.
返回
其他消息
2026-09-10
Norway's prime minister said on Sept. 9 that a drone nearly struck the plane carrying Ukrainian President Volodymyr Zelenskiy on a flight from Moldova to Oslo, but did not disclose the source or how close the drone came. Zelenskiy arrived in Oslo on Sept. 8 and attended the funeral of the late King Harald V on Sept. 9; Ukrainian authorities have not yet commented.
Norway's prime minister said on Sept. 9 that a drone nearly struck the plane carrying Ukrainian President Volodymyr Zelenskiy on a flight from Moldova to Oslo, but did not disclose the source or how close the drone came. Zelenskiy arrived in Oslo on Sept. 8 and attended the funeral of the late King Harald V on Sept. 9; Ukrainian authorities have not yet commented.
2026-09-10
David Samra, a major shareholder in Novartis (NVS.N), urged a board overhaul to improve governance, saying the company's acquisition record has been "disappointing" and pressing chairman Giovanni Caforio to act. Samra said the board should replace or upgrade the team responsible for deals, calling their performance at best "mediocre." His demand follows Tuesday's late-stage trial failure of a muscular dystrophy candidate from Novartis's $12bn acquisition of US firm Avidity, which sent the stock
David Samra, a major shareholder in Novartis (NVS.N), urged a board overhaul to improve governance, saying the company's acquisition record has been "disappointing" and pressing chairman Giovanni Caforio to act. Samra said the board should replace or upgrade the team responsible for deals, calling their performance at best "mediocre." His demand follows Tuesday's late-stage trial failure of a muscular dystrophy candidate from Novartis's $12bn acquisition of US firm Avidity, which sent the stock down more than 10% and wiped nearly $30bn off market value. Results for the heart drug pelacarsen disappointed investors the previous day.
Chat with us
, powered by
LiveChat